These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17572194)

  • 1. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
    Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
    Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
    Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
    Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
    Eifler JB; Feng Z; Lin BM; Partin MT; Humphreys EB; Han M; Epstein JI; Walsh PC; Trock BJ; Partin AW
    BJU Int; 2013 Jan; 111(1):22-9. PubMed ID: 22834909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
    Huang Y; Isharwal S; Haese A; Chun FK; Makarov DV; Feng Z; Han M; Humphreys E; Epstein JI; Partin AW; Veltri RW
    BJU Int; 2011 May; 107(10):1562-9. PubMed ID: 20875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
    JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
    Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
    Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of 2001 Partin tables in Turkey: a multicenter study.
    Eskicorapci SY; Karabulut E; Türkeri L; Baltaci S; Cal C; Toktas G; Akpinar H; Ozer G; Sozen S; Tokuc R; Lekili M; Soylu A; Albayrak S; Sahin H; Alpar R; Ozen H
    Eur Urol; 2005 Feb; 47(2):185-9. PubMed ID: 15661412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new nomogram to predict pathologic outcome following radical prostatectomy.
    Crippa A; Srougi M; Dall'Oglio MF; Antunes AA; Leite KR; Nesrallah LJ; Ortiz V
    Int Braz J Urol; 2006; 32(2):155-64. PubMed ID: 16650292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: comparison with western predictive tools using decision curve analysis.
    Jeong CW; Jeong SJ; Hong SK; Lee SB; Ku JH; Byun SS; Jeong H; Kwak C; Kim HH; Lee E; Lee SE
    Int J Urol; 2012 Sep; 19(9):846-52. PubMed ID: 22587373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
    Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
    Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
    Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
    J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the partin nomogram for prostate cancer in a national sample.
    Yu JB; Makarov DV; Sharma R; Peschel RE; Partin AW; Gross CP
    J Urol; 2010 Jan; 183(1):105-11. PubMed ID: 19913246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Stop-Shop Whole-Body
    Thalgott M; Düwel C; Rauscher I; Heck MM; Haller B; Gafita A; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
    Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
    J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are prostate carcinoma clinical stages T1c and T2 similar?
    Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
    Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
    Gupta RT; Brown AF; Silverman RK; Tay KJ; Madden JF; George DJ; Polascik TJ
    AJR Am J Roentgenol; 2016 Jul; 207(1):87-95. PubMed ID: 27064383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.